Home » Healthcare » Japan Human Insulin Market

Japan Human Insulin Market

UK Human Insulin Market By Device (Pens, Syringes, Others); By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); By Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Others); By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Japan Human Insulin Market Size 2023	USD 1,287.86 million
Japan Human Insulin Market, CGR	4.86%
Japan Human Insulin Market Size 2032	USD 1,976.41 million

Market Overview

Japan Human Insulin market size was valued at USD 1,287.86 million in 2023 and is anticipated to reach USD 1,976.41 million by 2032, at a CAGR of 4.86% during the forecast period (2023-2032).

The Japan human insulin market is driven by several key factors, including the rising prevalence of diabetes, the aging population, and increased awareness about diabetes management. As the number of diabetic patients continues to grow, there is a higher demand for effective insulin therapies. Additionally, advancements in insulin formulations, such as rapid-acting and long-acting insulins, are contributing to market growth. The increasing adoption of insulin pumps and continuous glucose monitoring systems is enhancing treatment outcomes, further propelling market expansion. Government initiatives and reimbursement policies aimed at improving healthcare accessibility and affordability are also boosting the market. Furthermore, the growing preference for biosimilar insulin products, due to their cost-effectiveness, is shaping the competitive landscape. These factors, combined with ongoing research and development efforts, are expected to drive sustained growth in the Japan human insulin market in the coming years.

The geographical distribution of the Japan human insulin market is influenced by factors such as population density, healthcare infrastructure, and regional diabetes prevalence. The Kanto region, including Tokyo, leads the market due to its high population, advanced medical facilities, and strong healthcare infrastructure. Kansai and Chubu regions follow closely, with significant demand driven by aging populations and increasing awareness of diabetes care. Kyushu, though smaller in market size, is also witnessing growing demand due to its aging demographic and improving healthcare access. Key players in the Japan human insulin market include global leaders such as Novo Nordisk, Eli Lilly, and Pfizer, along with local manufacturers like Biocon and Wockhardt. These companies dominate the market through their diverse product portfolios, including biosimilars and advanced insulin delivery systems. Their strategic focus on innovation and accessibility in Japan supports their strong position in the market.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The Japan human insulin market was valued at USD 1,287.86 million in 2023 and is expected to reach USD 1,976.41 million by 2032, growing at a CAGR of 4.86% during the forecast period (2023-2032).

The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.

Rising diabetes prevalence in Japan, driven by an aging population and lifestyle changes, is a key driver for increased insulin demand.
Advancements in insulin delivery systems, such as insulin pens, pumps, and continuous glucose monitoring, are enhancing treatment outcomes and adherence.
The shift towards biosimilar insulins is creating a more cost-effective market, making insulin therapy more accessible.
Market competition is intensifying, with global and local players like Novo Nordisk, Eli Lilly, and Biocon focusing on innovation and pricing strategies.
High costs of advanced diabetes care and market saturation are notable challenges for market expansion.
The Kanto region leads market demand due to its population density and advanced healthcare infrastructure, followed by Kansai and Chubu regions.

Report Scope

This report segments the Japan Human Insulin Market as follows:

Market Drivers

Rising Prevalence of Diabetes

One of the primary drivers of the Japan human insulin market is the rising prevalence of diabetes. For instance, Japan had over 11 million diabetic adults in 2021, with a prevalence rate of 11.8%. According to recent statistics, the number of individuals diagnosed with diabetes in Japan has steadily increased over the years, primarily due to an aging population and changing lifestyles. The International Diabetes Federation (IDF) reports that Japan has one of the highest rates of diabetes in the Asia-Pacific region, with millions of people living with both type 1 and type 2 diabetes. As a result, the demand for insulin products, particularly human insulin, has surged to manage the condition effectively. Increased healthcare awareness has also led to more frequent diagnoses and better disease management, which in turn boosts the demand for insulin therapies.

Advancements in Insulin Formulations and Delivery Systems

Advancements in insulin formulations and delivery systems are significantly influencing the growth of the human insulin market in Japan. For instance, rapid-acting and long-acting insulin formulations are enhancing treatment options and patient compliance. Innovations in rapid-acting and long-acting insulins have led to more effective and convenient treatment options for patients. These newer insulin types help maintain better blood glucose control, thus improving patient outcomes. Additionally, insulin delivery methods have evolved, with devices such as insulin pumps and continuous glucose monitors (CGMs) becoming increasingly popular. These advancements allow for better precision in insulin delivery and greater comfort for patients, further driving the market. The availability of more efficient and patient-friendly insulin options enhances treatment adherence, which ultimately supports market growth.

Government Initiatives and Healthcare Reforms

Government policies and initiatives aimed at improving healthcare access play a critical role in the expansion of the human insulin market in Japan. The Japanese government has introduced several measures to support the management of diabetes, including subsidies for insulin and diabetes-related treatment. Additionally, Japan’s healthcare system is known for its comprehensive coverage, ensuring that a wide range of diabetes treatments, including insulin therapies, are available to the public. The government’s commitment to reducing healthcare costs, improving access to medications, and addressing the growing burden of chronic diseases has helped fuel the demand for insulin products. These initiatives, combined with an aging population that requires ongoing care, create a favorable environment for market growth.

Growing Adoption of Biosimilar Insulin Products

The increasing adoption of biosimilar insulin products is reshaping the competitive landscape of the Japan human insulin market. Biosimilars offer a more cost-effective alternative to branded insulin, making diabetes management more affordable for patients and healthcare providers alike. With the expiration of patents for several leading insulin products, biosimilar options have gained significant traction in Japan’s market. These insulin products provide similar efficacy and safety to their branded counterparts, offering an attractive alternative for patients seeking more affordable treatment options. The growing availability of biosimilars, backed by regulatory approvals and increased healthcare cost containment efforts, is expected to drive significant growth in the market, particularly as more patients opt for budget-friendly alternatives.

Market Trends

Technological Advancements in Insulin Delivery

The Japan human insulin market is experiencing significant transformation driven by advancements in insulin delivery technology. For instance, insulin pens, pumps, and continuous glucose monitoring (CGM) systems are becoming increasingly prevalent among diabetes patients in Japan. Traditional insulin injections have been largely supplemented by more user-friendly alternatives such as insulin pens, which are gaining popularity due to their convenience and ease of use. These devices are especially beneficial for patients who require daily insulin administration, as they eliminate the need for cumbersome syringes. These technologies allow for real-time monitoring of glucose levels and provide more precise insulin delivery, which leads to better diabetes management and improved patient outcomes. The use of insulin pumps, in particular, has surged in Japan, as they provide patients with more flexibility and control over their insulin administration, thereby enhancing treatment adherence. As these innovations continue to evolve, they are expected to play a crucial role in optimizing diabetes care and driving the growth of the human insulin market.

Expansion of Biosimilar Insulin Products

Another prominent trend in the Japan human insulin market is the rising adoption of biosimilar insulin products. Biosimilars are designed to mimic the effects of already approved reference biologics and offer a more affordable alternative to traditional insulin products. The Japanese government has actively supported the development and adoption of biosimilars to reduce healthcare costs and improve access to essential diabetes treatments. The cost-effectiveness of biosimilars is particularly appealing to patients with chronic conditions like diabetes, as it makes ongoing insulin therapy more affordable. The approval of biosimilars, such as insulin glargine and insulin aspart, has led to increased market competition, benefiting both healthcare providers and patients. Additionally, the Japanese government has introduced reimbursement policies that favor the use of biosimilars, which has further facilitated their integration into diabetes care. This growing shift towards biosimilar insulin products is expected to continue as more patients and healthcare providers seek cost-efficient treatment options without compromising on quality.

Integration of Digital Health Solutions

The integration of digital health technologies is rapidly transforming the way diabetes care is delivered in Japan. Digital tools, such as mobile applications, smart insulin pens, and CGM systems, are increasingly being used to streamline diabetes management. These tools enable patients to track their blood glucose levels in real-time, receive personalized treatment recommendations, and share data with healthcare providers for more informed decision-making. For instance, the collaboration between Health2Sync’s diabetes management app and Novo Nordisk’s Mallya Cap, which monitors insulin pen usage, reflects the growing trend of digital health solutions that facilitate better patient engagement and adherence to prescribed therapies. Additionally, data from CGM devices, when paired with mobile apps, enables a more holistic approach to diabetes management by providing comprehensive insights into a patient’s glucose trends over time. As digital health technologies become more widespread and integrated into diabetes care, they are expected to play a pivotal role in improving treatment outcomes, increasing patient satisfaction, and further driving growth in the human insulin market.

Government Support and Healthcare Reforms

Government policies and healthcare reforms are critical factors influencing the dynamics of the human insulin market in Japan. The country’s universal healthcare system ensures that diabetes treatment, including insulin therapies, is widely accessible to the population. Regular health checkups and early detection of diabetes are strongly encouraged, which facilitates timely treatment and better long-term management of the disease. In recent years, the Japanese government has also focused on expanding reimbursement coverage for advanced diabetes care technologies, such as CGM devices and insulin pumps, making them more accessible to a larger segment of the population. For example, in 2023, the Ministry of Health, Labour and Welfare extended reimbursement coverage for CGM devices to include over a million more individuals, allowing for better monitoring of blood glucose levels and more precise insulin therapy. These efforts to improve accessibility and affordability of diabetes treatments are essential to managing the growing diabetes burden in Japan and are expected to further propel the human insulin market’s growth. The government’s ongoing support of diabetes care through these reforms reflects its commitment to ensuring that patients receive the best possible care and that treatment options, including human insulin, are readily available and financially accessible.

Market Challenges Analysis

High Cost of Advanced Diabetes Care

One of the key challenges facing the Japan human insulin market is the high cost of advanced diabetes care, particularly for cutting-edge insulin delivery devices and continuous glucose monitoring (CGM) systems. While Japan’s healthcare system offers universal coverage, the cost of insulin pumps, CGMs, and other advanced treatment options remains a barrier for many patients, especially those who are elderly or living with chronic conditions. Although government reimbursement policies have improved access to these devices, the out-of-pocket expenses can still be significant, particularly for patients without sufficient insurance coverage. This financial burden may lead to lower adoption rates of the most advanced technologies, hindering the effectiveness of insulin therapy and potentially limiting the growth of the human insulin market in Japan.

Market Saturation and Intense Competition

Another challenge in the Japan human insulin market is market saturation and intense competition among insulin providers. For instance, Japan’s human insulin market is highly competitive, with multiple pharmaceutical companies offering a range of insulin formulations. As the number of diabetes patients continues to rise, the market is becoming increasingly crowded, with numerous pharmaceutical companies vying for market share. Established players in the insulin market face significant competition from the growing number of biosimilars, which offer more affordable alternatives to branded insulins. While the availability of biosimilars has made insulin therapies more accessible, it has also led to pricing pressures, which can erode profit margins for manufacturers. Additionally, the presence of a variety of insulin options, including rapid-acting, long-acting, and mixed insulin formulations, adds to the complexity of treatment regimens, requiring patients to choose the most suitable option based on their individual needs. This competitive and saturated landscape presents challenges for companies seeking to differentiate their products and maintain market dominance in a cost-sensitive environment.

Market Opportunities

The Japan human insulin market presents significant opportunities driven by the increasing prevalence of diabetes and the growing demand for advanced treatment options. As the number of diabetic patients in Japan continues to rise, fueled by an aging population and changing lifestyles, there is an expanding need for effective insulin therapies. The growing adoption of biosimilar insulin products offers a unique opportunity for pharmaceutical companies to capture market share by providing more affordable alternatives to branded insulins. Additionally, innovations in insulin formulations, such as rapid-acting and long-acting insulins, are meeting the demand for more personalized and efficient treatment regimens, thereby improving patient outcomes and enhancing adherence to therapy. Companies that focus on developing and marketing these advanced insulin formulations have the opportunity to cater to a broader patient base and capture a larger portion of the market.

Another promising opportunity lies in the integration of digital health solutions with diabetes care. The increasing use of insulin pumps, continuous glucose monitoring (CGM) devices, and smart insulin pens represents a growing trend in the market. These technologies enable more precise management of insulin therapy and provide real-time data that help patients and healthcare providers make informed decisions. Companies that focus on developing user-friendly, connected devices or those that integrate their insulin products with digital health platforms can capitalize on this trend. Furthermore, government initiatives aimed at improving diabetes care, such as expanding reimbursement coverage for CGM devices and insulin pumps, create a favorable environment for market expansion. By aligning with these initiatives and offering innovative, cost-effective solutions, companies can position themselves as leaders in Japan’s rapidly evolving human insulin market.

Market Segmentation Analysis:

By Device:

The Japan human insulin market is segmented based on the type of device used for insulin administration, including pens, syringes, and others. Among these, insulin pens have emerged as the leading device due to their convenience, accuracy, and ease of use. Insulin pens are particularly favored by patients who require frequent injections, as they are portable, precise, and reduce the risk of dosing errors. This segment has gained popularity because of its user-friendly design, making it suitable for both home and on-the-go use. Syringes, on the other hand, are more traditional and continue to be widely used, especially in hospitals or for patients who prefer a more economical option. However, the convenience offered by insulin pens is gradually outpacing syringes. The “Others” segment, which includes insulin pumps and jet injectors, is also growing as these advanced delivery systems provide more precise control over insulin administration. Insulin pumps, which offer continuous insulin delivery, are increasingly being adopted by patients with type 1 diabetes for better long-term management of blood glucose levels.

By Indication:

The Japan human insulin market is also segmented based on the indication, including type 1 diabetes, type 2 diabetes, and gestational diabetes. Type 1 diabetes holds a significant share of the market due to its lifelong nature and the need for consistent insulin therapy. Patients with type 1 diabetes rely on insulin injections or pumps for survival, making this segment a major driver of market demand. Type 2 diabetes, which is more prevalent in Japan due to the aging population and sedentary lifestyles, also contributes significantly to the market. While type 2 diabetes patients may initially manage their condition with oral medications, many eventually require insulin therapy as the disease progresses. Gestational diabetes, although less common, also represents a growing segment of the market as more women are diagnosed during pregnancy. This segment often requires short-term insulin use, presenting opportunities for insulin manufacturers to develop specialized products for pregnant women. Overall, the rising prevalence of diabetes across all types of indications is propelling market growth in Japan.

Segments:

Based on Device:

Pens
Syringes
Others

Based on Indication:

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Based on Insulin:

Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others

Based on Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

Based on the Geography:

Kanto Region
Kansai Region
Chubu Region
Kyushu Region
Other Regions

Regional Analysis

Kanto region

The Kanto region, which includes the capital city Tokyo and surrounding prefectures, holds the largest share of the Japan human insulin market. Accounting for approximately 40% of the total market, this region benefits from its high population density, advanced healthcare facilities, and strong economic activity. Tokyo, as the epicenter of healthcare innovation and accessibility, sees widespread adoption of advanced insulin delivery systems, including insulin pens, pumps, and continuous glucose monitoring devices. The demand in Kanto is further fueled by a large number of healthcare professionals, research institutions, and pharmaceutical companies, creating a favorable environment for the growth of the insulin market.

Kansai region

The Kansai region, including major cities like Osaka, Kyoto, and Kobe, is the second-largest contributor to the Japan human insulin market, with a market share of around 25%. This region’s robust healthcare infrastructure and a large elderly population contribute to the high demand for diabetes care and insulin products. Kansai’s significant population of individuals with type 2 diabetes, compounded by an increasing awareness of diabetes management, drives the demand for insulin therapies. The region also benefits from a strong network of hospitals, clinics, and healthcare providers, ensuring that insulin products are readily accessible to patients.

Chubu region

The Chubu region, home to cities such as Nagoya, accounts for roughly 15% of the human insulin market in Japan. This region, known for its industrial and manufacturing strengths, has a moderate market share due to its large and aging population. As the region experiences an increase in the number of diabetes cases, especially type 2 diabetes, there is a growing demand for insulin products. The availability of medical facilities and diabetes care options, alongside a rise in health-conscious initiatives, is expected to propel the insulin market in Chubu.

Kyushu region

The Kyushu region, with cities like Fukuoka and Nagasaki, holds a market share of approximately 10%. Although it has a smaller share compared to Kanto, Kansai, and Chubu, Kyushu is witnessing a gradual increase in diabetes-related health concerns due to its aging population. The region’s demand for insulin is primarily driven by patients with type 2 diabetes, and government initiatives to improve healthcare accessibility are likely to boost the market further. The remaining 10% of the market share is attributed to other regions, which, while contributing less, continue to see incremental growth as healthcare access improves.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Tonghua Dongbao Pharmaceutical Co
Eli Lilly and Company
Julphar
Ypsomed

Competitive Analysis

The Japan human insulin market is highly competitive, with both global and local companies vying for market share. Leading players in the market include Novo Nordisk, Eli Lilly, Pfizer, Biocon, Wockhardt, MannKind Corporation, Lupin, Tonghua Dongbao Pharmaceutical Co., Julphar, and Ypsomed. The dominance of global pharmaceutical companies is notable, as they offer a broad portfolio of insulin products ranging from rapid-acting to long-acting insulin formulations, addressing the diverse needs of diabetic patients. These companies leverage strong brand recognition, extensive research and development capabilities, and established relationships with healthcare providers to maintain their competitive edge. Biosimilars are increasingly becoming a significant focus in the market, with several players offering cost-effective alternatives to branded insulin. This trend is driven by the growing demand for affordable diabetes care options, particularly as Japan’s aging population requires more accessible insulin therapies. Additionally, advanced insulin delivery systems, such as insulin pens, pumps, and continuous glucose monitoring devices, are becoming more widely adopted, further intensifying competition. Companies that provide integrated solutions, including both insulin products and delivery technologies, are gaining traction in the market. The rise of digital health solutions and patient-centric models also adds another layer of competition, as manufacturers aim to improve treatment outcomes and enhance patient compliance with their therapies. As the market evolves, companies must focus on innovation, pricing, and patient convenience to succeed in this competitive environment

Recent Developments

In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.

Market Concentration & Characteristics

Market concentration in the Japanese human insulin industry reflects a competitive landscape dominated by a few major players, with key companies holding significant market shares. This concentration is attributed to the high barriers to entry, including the need for advanced biotechnology infrastructure and regulatory approval processes. The industry is characterized by stringent government regulations that ensure the safety and efficacy of insulin products, as well as a well-established healthcare system that supports widespread access to insulin therapies. Major multinational pharmaceutical companies, alongside domestic players, lead the market by offering a variety of insulin formulations, such as rapid-acting, long-acting, and premixed insulins. Additionally, the growing demand for insulin due to Japan’s aging population and rising prevalence of diabetes further fuels market activity. Technological advancements, such as insulin pumps and continuous glucose monitoring systems, are also driving innovation, providing patients with more personalized and effective treatment options.

Report Coverage

The research report offers an in-depth analysis based on Device, Indication, Insulin, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

Japan’s aging population is expected to increase demand for human insulin as the prevalence of diabetes rises.
Technological innovations, such as insulin pumps and continuous glucose monitoring systems, will likely enhance treatment options.
The government will continue to regulate insulin products strictly to ensure patient safety and quality.
The increasing adoption of biosimilars will provide cost-effective alternatives to branded insulin products.
Domestic and international pharmaceutical companies are likely to invest more in research and development for novel insulin formulations.
The growth of personalized medicine may lead to more tailored insulin therapies for patients with specific needs.
Digital health solutions integrated with insulin delivery systems will create more efficient diabetes management tools.
Japan’s healthcare infrastructure will support broader insulin access and improve overall diabetes care.
The competition among key players will intensify, driving continuous product improvement and pricing adjustments.
Public health campaigns aimed at diabetes prevention will reduce long-term demand but may increase early intervention with insulin.

CHAPTER NO. 1 : INTRODUCTION 19

1.1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.1.2. Key Benefits for Stakeholders 19

1.1.3. Target Audience 20

1.1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. Human Insulin Market Snapshot 21

2.1.1. Japan Human Insulin Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23

3.1. Russia-Ukraine and Israel-Palestine War Impacts 23

CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 24

4.1. Introduction 24

4.2. Market Drivers 25

4.2.1. Driving Factor 1 Analysis 25

4.2.2. Driving Factor 2 Analysis 26

4.3. Market Restraints 27

4.3.1. Restraining Factor Analysis 27

4.4. Market Opportunities 28

4.4.1. Market Opportunity Analysis 28

4.5. Porter’s Five Forces Analysis 29

4.6. Value Chain Analysis 30

4.7. Buying Criteria 31

CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32

5.1. Import Analysis by Japan 32

5.1.1. Japan Human Insulin Market Import Volume/Revenue, By Japan, 2018 – 2023 32

5.2. Export Analysis by Japan 33

5.2.1. Japan Human Insulin Market Export Volume/Revenue, By Japan, 2018 – 2023 33

CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34

6.1. Demand Analysis by Japan 34

6.1.1. Japan Human Insulin Market Demand Volume/Revenue, By Japan, 2018 – 2023 34

6.2. Supply Analysis by Japan 35

6.2.1. Japan Human Insulin Market Supply Volume/Revenue, By Japan, 2018 – 2023 35

CHAPTER NO. 7 : PRODUCTION ANALYSIS 36

7.1. Production Analysis by Japan 36

7.1.1. Japan Human Insulin Market Production Volume/Revenue, By Japan, 2018 – 2023 36

CHAPTER NO. 8 : PRICE ANALYSIS 37

8.1. Price Analysis by Type 37

8.1.1. Japan Human Insulin Market Price, By Type, 2018 – 2023 37

8.1.2. Japan Type Market Price, By Type, 2018 – 2023 37

CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38

9.1. Key Raw Materials and Suppliers 38

9.2. Key Raw Materials Price Trend 38

CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39

10.1. Manufacturing Cost Analysis 39

10.2. Manufacturing Process 39

CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40

11.1. Company Market Share Analysis – 2023 40

11.1.1. Japan Human Insulin Market: Company Market Share, by Volume, 2023 40

11.1.2. Japan Human Insulin Market: Company Market Share, by Revenue, 2023 41

11.1.3. Japan Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 41

11.1.4. Japan Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 42

11.2. Japan Human Insulin Market Company Volume Market Share, 2023 43

11.3. Japan Human Insulin Market Company Revenue Market Share, 2023 44

11.4. Company Assessment Metrics, 2023 45

11.4.1. Stars 45

11.4.2. Emerging Leaders 45

11.4.3. Pervasive Players 45

11.4.4. Participants 45

11.5. Start-ups /SMEs Assessment Metrics, 2023 45

11.5.1. Progressive Companies 45

11.5.2. Responsive Companies 45

11.5.3. Dynamic Companies 45

11.5.4. Starting Blocks 45

11.6. Strategic Developments 46

11.6.1. Acquisitions & Mergers 46

New Product Launch 46

Japan Expansion 46

11.7. Key Players Product Matrix 47

CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48

12.1. PESTEL 48

12.1.1. Political Factors 48

12.1.2. Economic Factors 48

12.1.3. Social Factors 48

12.1.4. Technological Factors 48

12.1.5. Environmental Factors 48

12.1.6. Legal Factors 48

12.2. Adjacent Market Analysis 48

CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY TYPE SEGMENT ANALYSIS 49

13.1. Human Insulin Market Overview, by Type Segment 49

13.1.1. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

13.1.2. Human Insulin Market Attractiveness Analysis, By Type 51

13.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 51

13.1.4. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

13.2. Pens 53

13.3. Syringes 54

13.4. Others 55

13.5. Type 4 56

13.6. Type 5 57

CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY APPLICATION SEGMENT ANALYSIS 58

14.1. Human Insulin Market Overview, by Application Segment 58

14.1.1. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

14.1.2. Human Insulin Market Attractiveness Analysis, By Application 60

14.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 60

14.1.4. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

14.2. Type 1 Diabetes 62

14.3. Type 2 Diabetes 63

14.4. Gestational Diabetes 64

14.5. Application 4 65

14.6. Application 5 66

CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY END-USER SEGMENT ANALYSIS 67

15.1. Human Insulin Market Overview, by End-user Segment 67

15.1.1. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

15.1.2. Human Insulin Market Attractiveness Analysis, By End-user 69

15.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 69

15.1.4. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

15.2. Rapid-acting insulin 71

15.3. Short-acting insulin 72

15.4. Intermediate-acting insulin 73

15.5. Others 74

15.6. End-user 5 75

CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76

16.1. Human Insulin Market Overview, by Technology Segment 76

16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 78

16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78

16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

16.2. Technology 1 80

16.3. Technology 2 81

16.4. Technology 3 82

CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83

17.1. Human Insulin Market Overview, by Distribution Channel Segment 83

17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 85

17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85

17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

17.2. Hospital Pharmacies 87

17.3. Drug Stores and Retail Pharmacies 88

17.4. Online Providers 89

17.5. Distribution Channel 4 90

17.6. Distribution Channel 5 91

CHAPTER NO. 18 : HUMAN INSULIN MARKET – JAPAN ANALYSIS 92

18.1. Type 92

18.1.1. Japan Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 92

18.2. Japan Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 92

18.3. Application 93

18.3.1. Japan Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 93

18.3.2. Japan Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 93

18.4. End-user 94

18.4.1. Japan Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 94

18.4.2. Japan Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 94

18.5. Technology 95

18.5.1. Japan Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 95

18.5.2. Japan Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 95

18.6. Distribution Channel 96

18.6.1. Japan Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96

18.6.2. Japan Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96

CHAPTER NO. 19 : COMPANY PROFILES 97

19.1. Novo Nordisk A/S 97

19.1.1. Company Overview 97

19.1.2. Product Portfolio 97

19.1.3. Swot Analysis 97

19.1.4. Business Strategy 98

19.1.5. Financial Overview 98

19.1.6. MannKind Corporation 99

19.1.7. Pfizer 99

19.1.8. Wockhardt 99

19.1.9. Biocon 99

19.1.10. Lupin 99

19.1.11. Tonghua Dongbao Pharmaceutical Co 99

19.1.12. Eli Lilly and Company 99

19.1.13. Julphar 99

19.1.14. Ypsomed 99

19.1.15. Company 11 99

19.1.16. Company 12 99

19.1.17. Company 13 99

19.1.18. Company 14 99

CHAPTER NO. 20 : RESEARCH METHODOLOGY 100

20.1. Research Methodology 100

20.1.1. Phase I – Secondary Research 101

20.1.2. Phase II – Data Modeling 101

Company Share Analysis Model 102

Revenue Based Modeling 102

20.1.3. Phase III – Primary Research 103

20.1.4. Research Limitations 104

Assumptions 104

List of Figures

FIG NO. 1. Japan Human Insulin Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for Japan Human Insulin Market 29

FIG NO. 3. Value Chain Analysis for Japan Human Insulin Market 30

FIG NO. 4. Japan Human Insulin Market Import Volume/Revenue, By Japan, 2018 – 2023 32

FIG NO. 5. Japan Human Insulin Market Export Volume/Revenue, By Japan, 2018 – 2023 33

FIG NO. 6. Japan Human Insulin Market Demand Volume/Revenue, By Japan, 2018 – 2023 34

FIG NO. 7. Japan Human Insulin Market Supply Volume/Revenue, By Japan, 2018 – 2023 35

FIG NO. 8. Japan Human Insulin Market Production Volume/Revenue, By Japan, 2018 – 2023 36

FIG NO. 9. Japan Human Insulin Market Price, By Type, 2018 – 2023 37

FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38

FIG NO. 11. Manufacturing Cost Analysis 39

FIG NO. 12. Manufacturing Process 39

FIG NO. 13. Company Share Analysis, 2023 40

FIG NO. 14. Company Share Analysis, 2023 41

FIG NO. 15. Company Share Analysis, 2023 41

FIG NO. 16. Company Share Analysis, 2023 42

FIG NO. 17. Human Insulin Market – Company Volume Market Share, 2023 43

FIG NO. 18. Human Insulin Market – Company Revenue Market Share, 2023 44

FIG NO. 19. Human Insulin Market Revenue Share, By Type, 2023 & 2032 50

FIG NO. 20. Market Attractiveness Analysis, By Type 51

FIG NO. 21. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 51

FIG NO. 22. Human Insulin Market Revenue, By Type, 2018, 2023, 2027 & 2032 52

FIG NO. 23. Japan Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 53

FIG NO. 24. Japan Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 54

FIG NO. 25. Japan Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 55

FIG NO. 26. Japan Human Insulin Market for Type 4, Revenue (USD Million) 2018 – 2032 56

FIG NO. 27. Japan Human Insulin Market for Type 5, Revenue (USD Million) 2018 – 2032 57

FIG NO. 28. Human Insulin Market Revenue Share, By Application, 2023 & 2032 59

FIG NO. 29. Market Attractiveness Analysis, By Application 60

FIG NO. 30. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 60

FIG NO. 31. Human Insulin Market Revenue, By Application, 2018, 2023, 2027 & 2032 61

FIG NO. 32. Japan Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 62

FIG NO. 33. Japan Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 63

FIG NO. 34. Japan Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 64

FIG NO. 35. Japan Human Insulin Market for Application 4, Revenue (USD Million) 2018 – 2032 65

FIG NO. 36. Japan Human Insulin Market for Application 5, Revenue (USD Million) 2018 – 2032 66

FIG NO. 37. Human Insulin Market Revenue Share, By End-user, 2023 & 2032 68

FIG NO. 38. Market Attractiveness Analysis, By End-user 69

FIG NO. 39. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 69

FIG NO. 40. Human Insulin Market Revenue, By End-user, 2018, 2023, 2027 & 2032 70

FIG NO. 41. Japan Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 71

FIG NO. 42. Japan Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 72

FIG NO. 43. Japan Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 73

FIG NO. 44. Japan Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 74

FIG NO. 45. Japan Human Insulin Market for End-user 5, Revenue (USD Million) 2018 – 2032 75

FIG NO. 46. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 77

FIG NO. 47. Market Attractiveness Analysis, By Technology 78

FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78

FIG NO. 49. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79

FIG NO. 50. Japan Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 80

FIG NO. 51. Japan Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 81

FIG NO. 52. Japan Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 82

FIG NO. 53. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 84

FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85

FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85

FIG NO. 56. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86

FIG NO. 57. Japan Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 87

FIG NO. 58. Japan Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 88

FIG NO. 59. Japan Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 89

FIG NO. 60. Japan Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90

FIG NO. 61. Japan Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91

FIG NO. 62. Research Methodology – Detailed View 100

FIG NO. 63. Research Methodology 101

List of Tables

TABLE NO. 1. : Japan Human Insulin Market: Snapshot 18

TABLE NO. 2. : Drivers for the Human Insulin Market: Impact Analysis 22

TABLE NO. 3. : Restraints for the Human Insulin Market: Impact Analysis 24

TABLE NO. 4. : Japan Human Insulin Market Revenue, By Type, 2018 – 2023 34

TABLE NO. 5. : Key Raw Materials & Suppliers 35

TABLE NO. 6. : Japan Human Insulin Market Revenue, By Type, 2018 – 2023 (USD Million) 89

TABLE NO. 7. : Japan Human Insulin Market Revenue, By Type, 2024 – 2032 (USD Million) 89

TABLE NO. 8. : Japan Human Insulin Market Revenue, By Application, 2018 – 2023 (USD Million) 90

TABLE NO. 9. : Japan Human Insulin Market Revenue, By Application, 2024 – 2032 (USD Million) 90

TABLE NO. 10. : Japan Human Insulin Market Revenue, By End-user, 2018 – 2023 (USD Million) 91

TABLE NO. 11. : Japan Human Insulin Market Revenue, By End-user, 2024 – 2032 (USD Million) 91

TABLE NO. 12. : Japan Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 92

TABLE NO. 13. : Japan Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 92

TABLE NO. 14. : Japan Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93

TABLE NO. 15. : Japan Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93

Frequently Asked Questions

What is the current size of the Japan Human Insulin?

The market was valued at USD 1,287.86 million in 2023 and is projected to reach USD 1,976.41 million by 2032.

What factors are driving the growth of the Japan Human Insulin?

Key drivers include rising diabetes prevalence, aging population, biosimilar adoption, and advancements in insulin delivery technologies.

What are some challenges faced by the Japan Human Insulin?

Challenges include high costs of advanced diabetes care and market saturation with intense competition.

Who are the major players in the Japan Human Insulin?

Leading players include Novo Nordisk, Eli Lilly, Pfizer, Biocon, Wockhardt, MannKind, and Ypsomed.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –